Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Best Research Peptides for Erectile Dysfunction Research: Mechanistic Comparison

Before selecting a peptide, clarify the pathophysiological model you're investigating. Central vs peripheral, hormonal vs neurovascular, acute vs chronic. PT-141 (bremelanotide) Melanocortin-4 receptor agonist. Central dopaminergic activation in hypothalamus M

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • Before selecting a peptide, clarify the pathophysiological model you're investigating. Central vs peripheral, hormonal vs neurovascular, acute vs chronic.
  • PT-141 (bremelanotide)
  • Melanocortin-4 receptor agonist. Central dopaminergic activation in hypothalamus
  • MC4R
  • Subcutaneous
  • ~2.7 hours
  • 1–2 mg/kg SC
  • Best for central/neurogenic ED models; requires CNS penetration; works independently of peripheral vascular function
  • Kisspeptin-10
  • GnRH pulse generator. Upstream hormonal modulation via KISS1R
  • KISS1R (GPR54)
  • IV infusion or repeated bolus
  • <30 minutes
  • 1 nmol/kg/hour IV
  • Best for hypogonadal or age-related models; requires intact HPG axis; ineffective in primary testicular failure
  • VIP (vasoactive intestinal peptide)
  • cAMP-mediated smooth muscle relaxation. Bypasses NO pathway
  • VPAC1, VPAC2
  • Intracavernosal or systemic + DPP-4 inhibitor
  • <2 minutes
  • 10–50 nmol intracavernosal
  • Best for diabetic or post-surgical models with impaired NO signaling; extremely short half-life limits systemic use
  • Melanotan II
  • Non-selective melanocortin agonist (MC1R, MC3R, MC4R)
  • MC1R, MC3R, MC4R, MC5R
  • ~30 minutes
  • 0.5–1 mg/kg SC
  • Broad melanocortin activation; more side effects than PT-141; investigational only. No clinical approval
  • Angiotensin-(1–7)
  • Mas receptor-mediated vasodilation. Endothelial function improvement
  • Mas receptor
  • Subcutaneous (chronic)
  • ~10 minutes
  • 300 µg/kg/day SC (chronic)
  • Early preclinical stage; targets endothelial dysfunction; no human ED data yet; relevant for hypertensive models

Related resources

More comparisons